MX366493B - Composiciones y su uso en el tratamiento de cánceres cerebrales. - Google Patents

Composiciones y su uso en el tratamiento de cánceres cerebrales.

Info

Publication number
MX366493B
MX366493B MX2015007093A MX2015007093A MX366493B MX 366493 B MX366493 B MX 366493B MX 2015007093 A MX2015007093 A MX 2015007093A MX 2015007093 A MX2015007093 A MX 2015007093A MX 366493 B MX366493 B MX 366493B
Authority
MX
Mexico
Prior art keywords
protein
sequence
maraba
includes seq
compositions
Prior art date
Application number
MX2015007093A
Other languages
English (en)
Other versions
MX2015007093A (es
Inventor
David Stojdl
John Cameron Bell
Original Assignee
Turnstone Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turnstone Lp filed Critical Turnstone Lp
Publication of MX2015007093A publication Critical patent/MX2015007093A/es
Publication of MX366493B publication Critical patent/MX366493B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una partícula viral aislada que tiene un genoma que incluye cuadros de lectura abiertos, que codifica para: proteínas Maraba N, P y L, o variantes de las mismas; así como la proteína Maraba M o proteína delta SiM, o variantes de las mismas; y una proteína Bahía Grande G, una proteína LCMV G, o una proteína Ébola G. La proteína Maraba N puede tener una secuencia que incluye SEQ ID NO. 1. La proteína Maraba L puede tener una secuencia que incluye SEQ ID NO. 1. La proteína Maraba L puede tener una secuencia que incluye SEQ ID NO. 3. Las proteínas Maraba M y delta 1M pueden tener una secuencia que incluye SEQ ID NO. 4 y 5, respectivamente. La proteína Bahía Grande G puede tener una secuencia que incluye SEQ ID NO: 6. La proteína LCMV G puede tener una secuencia que incluye SEQ ID NO. 7. La proteína Ébola G puede tener una secuencia que incluye SEQ ID NO. 8.
MX2015007093A 2012-12-12 2012-12-12 Composiciones y su uso en el tratamiento de cánceres cerebrales. MX366493B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2012/050893 WO2014089668A1 (en) 2012-12-12 2012-12-12 Compositions and methods for the treatment of brain cancers

Publications (2)

Publication Number Publication Date
MX2015007093A MX2015007093A (es) 2016-01-12
MX366493B true MX366493B (es) 2019-07-10

Family

ID=50933623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007093A MX366493B (es) 2012-12-12 2012-12-12 Composiciones y su uso en el tratamiento de cánceres cerebrales.

Country Status (11)

Country Link
US (1) US20150307559A1 (es)
EP (1) EP2931880B1 (es)
JP (1) JP6162818B2 (es)
CN (1) CN105008524A (es)
AU (1) AU2012396787B9 (es)
BR (1) BR112015013669A2 (es)
CA (1) CA2894618A1 (es)
IL (1) IL239374B (es)
MX (1) MX366493B (es)
RU (1) RU2705244C2 (es)
WO (1) WO2014089668A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
CA2872045A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
EP3624825A4 (en) * 2017-05-19 2021-03-10 Georgia State University Research Foundation, Inc. RECOMBINANT ONCOLYTIC VIRUS
US12091434B2 (en) * 2017-09-22 2024-09-17 Centre National De La Recherche Scientifique (Cnrs) Mutated glycoprotein of vesicular stomatitis virus
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003784A3 (cs) * 2000-09-22 2003-11-12 Virxsys Corporation Zlepšené podmíněně se replikující vektory, způsoby jejich produkce a jejich použití
EP2839837B1 (en) * 2006-09-15 2019-05-08 Children's Hospital of Eastern Ontario Research Institute Inc. Oncolytic farmington rhabdovirus
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren

Also Published As

Publication number Publication date
RU2015128078A (ru) 2019-03-27
AU2012396787B2 (en) 2019-09-19
BR112015013669A2 (pt) 2017-11-14
US20150307559A1 (en) 2015-10-29
JP2016501528A (ja) 2016-01-21
WO2014089668A1 (en) 2014-06-19
EP2931880A1 (en) 2015-10-21
IL239374A0 (en) 2015-07-30
AU2012396787A1 (en) 2015-07-02
EP2931880B1 (en) 2019-03-20
CN105008524A (zh) 2015-10-28
AU2012396787B9 (en) 2019-10-03
IL239374B (en) 2021-03-25
RU2705244C2 (ru) 2019-11-06
EP2931880A4 (en) 2016-05-18
RU2015128078A3 (es) 2019-03-27
JP6162818B2 (ja) 2017-07-12
CA2894618A1 (en) 2014-06-19
MX2015007093A (es) 2016-01-12

Similar Documents

Publication Publication Date Title
MX366493B (es) Composiciones y su uso en el tratamiento de cánceres cerebrales.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2019006467A (es) Composiciones y métodos para mejorar la expresión génica.
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
SG10201903381TA (en) Artificial nucleic acid molecules
NZ731571A (en) T cell receptors
MY161252A (en) Viral inactivation using improved solvent-detergent method
IN2014CN00688A (es)
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
IN2015DN03206A (es)
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2016130628A8 (en) Griffithsin mutants
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
PH12018500155A1 (en) Recombinant orf virus vector
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
FI20115328A (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
WO2018132821A3 (en) Elastomeric proteins
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
EA201991702A1 (ru) Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты
AU2014218508B2 (en) Manipulation of self-incompatibility in plants

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TURNSTONE LIMITED PARTNERSHIP

FG Grant or registration